文献速递肝病消化道肿瘤与早癌

嘌呤合成代谢通过m6A介导的表观转录组调控造成肝细胞癌的治疗脆弱性

Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m 6 A-mediated epitranscriptomic regulation.
PubMed 文献 · Hepatology · 2023-04-26

该研究对62例肝细胞癌患者的肿瘤及配对非肿瘤肝组织进行转录组和代谢组分析,发现嘌呤合成基因上调而降解基因受抑,高嘌呤合成与特定体细胞突变特征及患者预后相关。机制上,嘌呤合成增强通过上调RNA m6A修饰促进DNA损伤修复(DDR)机制的表观转录组失调,高嘌呤合成型肝细胞癌对DDR靶向药物敏感而对标准治疗不敏感,此相关性在5个独立队列共724例患者中得到验证,并在5种肝细胞癌细胞系体内外实验中证实。

要点

  • 肝细胞癌肿瘤中嘌呤合成基因多数上调、嘌呤降解基因受抑。
  • 高嘌呤合成与特定体细胞突变特征相关并关联患者预后。
  • 高嘌呤合成型肝细胞癌对DDR靶向药物敏感,对标准肝细胞癌治疗不敏感。

核心结论

  • 嘌呤合成代谢在调控DNA损伤修复中起核心作用,并可在肝细胞癌中被治疗性利用。

研究设计与样本

  • 对62例肝细胞癌患者的肿瘤及配对非肿瘤肝组织进行转录组和代谢组分析。
  • 在5个独立肝细胞癌队列共724例患者中验证高嘌呤合成与临床结局的相关性。
  • 在5种肝细胞癌细胞系中于体外和体内验证高嘌呤合成对DDR靶向药物敏感性的决定作用。

主要发现

  • 肝细胞癌肿瘤中嘌呤合成通路多数基因上调,嘌呤降解通路基因受抑。
  • 高嘌呤合成与独特的体细胞突变特征相关,该特征与患者预后相关。
  • 增加嘌呤合成通过上调RNA N6-甲基腺苷(m6A)修饰促进DNA损伤修复机制的表观转录组失调。
  • 高嘌呤合成型肝细胞癌对DDR靶向药物敏感,对标准肝细胞癌治疗不敏感,该关联与5个独立队列共724例患者的临床结局一致。
  • 在5种肝细胞癌细胞系体外和体内实验中,高嘌呤合成决定对DDR靶向药物的敏感性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Purines are building blocks for the cellular genome, and excessive purine nucleotides are seen in tumors. However, how purine metabolism is dysregulated in tumors, and impacting tumorigenesis remains elusive. APPROACH AND RESULTS: Transcriptomic and metabolomic analyses of purine biosynthesis and purine degradation pathways were performed in the tumor and associated nontumor liver tissues obtained from 62 patients with HCC, one of the most lethal cancers worldwide. We found that most genes in purine synthesis are upregulated, while genes in purine degradation are inhibited in HCC tumors. High purine anabolism is associated with unique somatic mutational signatures linked to patient prognosis. Mechanistically, we discover that increasing purine anabolism promotes epitranscriptomic dysregulation of DNA damage repairing (DDR) machinery through upregulating RNA N6-methyladenosine (m 6 A) modification. High purine anabolic HCC is sensitive to DDR-targeting agents but not to standard HCC treatments, correlating with the clinical outcomes in 5 independent HCC cohorts containing 724 patients. We further showed that high purine anabolism determines the sensitivity to DDR-targeting agents in 5 HCC cell lines in vitro and in vivo . CONCLUSIONS: Our results reveal a central role of purine anabolism in regulating DDR, which could be therapeutically exploited in HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hung MH, Chang CW, Wang KC, et al. Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m 6 A-mediated epitranscriptomic regulation. Hepatology. 2023. PMID: 37094826. doi:10.1097/HEP.0000000000000420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。